{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:50:35Z","timestamp":1791435035777,"version":"4.3.3"},"reference-count":43,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Ophthalmologica"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To describe the treatment results with adalimumab in chronic paediatric uveitis, not associated with juvenile idiopathic arthritis (JIA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Medical records of children with non\u2010JIA\u2010uveitis were reviewed retrospectively. Children without an underlying systemic disease were pre\u2010screened with brain magnetic resonance imaging (MRI) to exclude white matter abnormalities\/demyelination.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty\u2010six patients were pre\u2010screened with brain MRI, of whom adalimumab was contraindicated in six patients (23%) with non\u2010anterior uveitis. Forty\u2010three patients (81 eyes) were included. Disease inactivity was achieved in 91% of the patients after a median of three months (3\u201333). Best\u2010corrected visual acuity (BCVA) improved from 0.16\u00a0\u00b1\u00a00.55 logarithm of the minimum angle of resolution (logMAR) at baseline to 0.05\u00a0\u00b1\u00a00.19 logMAR at 24\u00a0months (p\u00a0=\u00a00.015). The median dosage of systemic corticosteroids was reduced to 0\u00a0mg\/day at 24\u00a0months of follow\u2010up (versus 10\u00a0mg\/day at baseline; p\u00a0&lt;\u00a00.001). Adalimumab was discontinued in thirteen children due to ineffectiveness (<jats:italic>n<\/jats:italic>\u00a0=\u00a08), side effects (<jats:italic>n<\/jats:italic>\u00a0=\u00a01), long\u2010term inactivity of uveitis (<jats:italic>n<\/jats:italic>\u00a0=\u00a03) or own initiative (<jats:italic>n<\/jats:italic>\u00a0=\u00a01). Relapse of uveitis occurred in 19 (49%) patients, 5 (26%) of them without an identifiable cause.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Adalimumab is effective in the treatment of non\u2010JIA\u2010uveitis in paediatric patients by achieving disease inactivity in the majority of the patients, improving BCVA and decreasing the dose of corticosteroids. Adverse events and side effects are limited. Pre\u2010screening with MRI of the brain is recommended in paediatric patients with intermediate and panuveitis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/aos.15012","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T05:19:58Z","timestamp":1631855998000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Clinical benefits and potential risks of adalimumab in non\u2010JIA chronic paediatric uveitis"],"prefix":"10.1111","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7936-519X","authenticated-orcid":false,"given":"Carlyn V.","family":"Kouwenberg","sequence":"first","affiliation":[{"name":"Department of Ophthalmology University Medical Centre Utrecht  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viera","family":"Koopman\u2010Kalinina Ayuso","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology University Medical Centre Utrecht  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joke H.","family":"de Boer","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology University Medical Centre Utrecht  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000298"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.08.031"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130302"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2010.01.014"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2015.06.004"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3890-4"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191390"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2017.1334469"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1076\/ocii.8.4.251.6459"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40484"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2019.06.007"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509852"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2010.01.016"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-017-0742-1"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00104"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.04.009"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2011.255"},{"key":"e_1_2_7_20_1","first-page":"1043","article-title":"Anti\u2010adalimumab antibodies in juvenile idiopathic arthritis\u2010related uveitis","volume":"35","author":"Leinonen ST","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_21_1","first-page":"1","article-title":"Escalation to weekly adalimumab for the treatment of ocular inflammation","volume":"00","author":"Liberman P","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000723"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S160431"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/461078"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31339-3"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2016.07.002"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212089"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614160"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.4.4.637"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14535"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2010.05.017"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22214"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2015.1022213"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2018-315060"},{"key":"e_1_2_7_35_1","unstructured":"Society EG(2014): The Guidelines project was entirely supported by the European Glaucoma Society Foundation.: Ncbi 2"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40674-017-0057-z"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.12.039"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000516"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.12.003"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-008-9263-x"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2013.01.031"},{"key":"e_1_2_7_42_1","first-page":"1","article-title":"Tocilizumab as an effective treatment option in children with refractory intermediate and panuveitis","volume":"00","author":"Wennink RAW","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/IIO.0000000000000072"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2015.1136385"}],"container-title":["Acta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aos.15012","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/aos.15012","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aos.15012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T15:52:55Z","timestamp":1692978775000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/aos.15012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1111\/aos.15012"],"URL":"https:\/\/doi.org\/10.1111\/aos.15012","archive":["Portico"],"relation":{},"ISSN":["1755-375X","1755-3768"],"issn-type":[{"value":"1755-375X","type":"print"},{"value":"1755-3768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,16]]},"assertion":[{"value":"2020-09-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}